September 7, 2026 · Six papers · About 3 minutes A selective research digest. Abstract-based summaries unless noted—not clinical recommendations.
General anesthesia · Multicenter randomized trial · August 12, 2026
TIVA did not improve days alive and at home after major noncardiac surgery
In 2,508 adults aged 50 or older, propofol maintenance and inhalational anesthesia produced similar 30-day home-time outcomes. TIVA patients reported less nausea/vomiting, thirst and hoarseness.
Takeaway: Symptom benefits did not translate into more time at home. Caveat: The trial was open-label and does not settle rare safety outcomes.
Results & limitation
Mean days alive and at home: 22.5 versus 22.4; incidence rate ratio 1.00 (95% CI 0.99–1.02). This was an open-label trial in 49 UK hospitals. Two certain/probable awareness cases occurred in the TIVA arm; rare-event counts alone cannot establish comparative safety.
Airway / critical care · Multicenter randomized trial · Online December 9, 2025
Ketamine did not lower mortality versus etomidate for critically ill intubations
The trial found no significant reduction in in-hospital death by day 28 with ketamine. Cardiovascular collapse during intubation was more frequent with ketamine: 22.1% versus 17.0%.
Takeaway: The expected mortality benefit was not demonstrated, and collapse favored etomidate. Caveat: This was an emergency/ICU population, not elective surgical patients.
Results & limitation
Collapse risk difference: 5.1 percentage points (95% CI 1.9–8.3). Conducted in 14 US emergency departments and ICUs; this is not an elective operating-room population. Included as an earlier important trial, not presented as a new September publication.
Cancer surgery · Meta-analysis of randomized trials · August 17, 2026
Propofol has not shown a cancer-survival advantage over volatile anesthesia
Across 11 studies involving 7,811 patients, the pooled estimates did not demonstrate better overall or recurrence-free survival with propofol.
Takeaway: The pooled randomized evidence does not support a survival advantage. Caveat: Smaller effects and differences between cancer types remain possible.
Results & limitation
Overall survival HR 1.05 (95% CI 0.94–1.17); recurrence-free survival HR 1.06 (0.95–1.19). Interpretation: these findings do not establish equivalence for every cancer type or rule out smaller effects.
Analgesia · Systematic review & meta-analysis · August 12, 2026
Multimodal anesthesia reduced opioid use and PONV—not clearly 24-hour pain
The review included 21 randomized trials and 1,828 patients. Adding at least two analgesic modalities to opioids reduced opioid consumption and postoperative nausea/vomiting, but a pain benefit at 24 hours remained uncertain.
Takeaway: Opioid sparing and pain relief are not interchangeable outcomes. Caveat: Certainty ranged from moderate to very low; no single optimal regimen emerged.
Results & limitation
PONV RR 0.59 (95% CI 0.44–0.77; low certainty). Opioid use fell by 7.0 mg morphine equivalents (95% CI −12.8 to −1.3; moderate certainty). Pain evidence was very low certainty; data were insufficient to pool recovery quality, PACU stay or pulmonary complications. This does not identify one optimal drug combination.
Regional anesthesia · Double-blind randomized trial · March 27, 2026
PENG block offered early PACU benefits, without better 24-hour recovery
Among 94 ambulatory hip-arthroscopy patients, preoperative PENG block did not improve 24-hour opioid consumption or quality of recovery compared with sham injection. Adjusted analyses favored the block for PACU opioid use and length of stay.
Takeaway: Early PACU gains did not persist in the primary recovery outcomes. Caveat: These results concern hip arthroscopy, not fracture surgery or arthroplasty.
Results & limitation
QoR-15 was 96.8 versus 101.0 (adjusted p=0.414). PACU differences were −9.5 morphine-milligram equivalents and −20.5 minutes. These secondary findings do not override the neutral primary outcomes; results should not be extrapolated to hip fracture or arthroplasty.
Obstetrics · Umbrella review · Online April 16, 2026
Evidence on induction drugs and obstetric awareness remains limited
The review identifies low-certainty evidence associating propofol with less accidental awareness than thiopental in obstetric surgery. Adequately powered randomized comparisons of awareness risk are lacking.
Takeaway: An awareness signal worth following, not a definitive comparison. Caveat: This finding alone does not capture maternal and neonatal trade-offs.
Scope & limitation
This is one finding from a broader review of pharmacological induction strategies for cesarean delivery—not a complete comparison of maternal and neonatal risks. The authors note that overlapping primary trials can distort umbrella reviews. Do not read the awareness signal as a universal drug-selection rule.